Improvement of @entity4346 and arrhythmias after XXXX -induced GH and IGF-I decrease in @entity2012 . A prospective multi-center study.

@entity1 @entity64 @entity2012 @entity4346 @entity18245 @entity1943
We report the results of a prospective Italian multi-center study of the effects of @entity18245 , a slow-release @entity1943 analog, on left ventricular morphology and function and on the prevalence of ventricular arrhythmic events in 19 @entity1 with active, newly diagnosed, uncomplicated @entity2012 . Cardiac features were evaluated with Doppler-echocardiography and 24-h Holter ECG monitoring at baseline and after 6 months of @entity18245 therapy. Fifteen @entity1 (78.9%) had @entity4346 . @entity18245 treatment significantly decreased the left ventricular mass (127.8+/-6.9 vs 140.7+/-7.1 g/m2, p<0.001) and @entity4346 significantly disappeared in 6 of these @entity1 . Treatment did not significantly affect systolic function, whereas it increased the Doppler-derived early-to-late mitral flow velocity, (E/A) ratio, of early-to-late trans-mitral flow velocity (1.34+/-0.1 vs 1.09+/-0.06, p=0.001). @entity64 volume was slightly but not significantly increased after treatment, whereas systolic BP was significantly higher (134+/-14 vs 129+/-13 mmHg, p<0.05). The 24-h mean heart rate was significantly reduced after treatment (66.5+/-11 vs 71.5+/-20 beats/min, p<0.05). Supra-ventricular premature beats (>50/24 h) occurred in 16.6% of @entity1 and were unaffected by treatment. Differently, ventricular premature beats (>50/24 h) occurred in 33.3% of @entity1 before treatment vs 16.5%, after treatment. In conclusion, @entity18245 reduced the left ventricular mass, and improved ventricular filling and ventricular arrhythmic profile.
